![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Identifying HCV genotype 2/3 patients who could receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
|
|
|
Reported by Jules Levin
AASLD Oct 31-Nov 3 2009 Boston, MA
Mitchell L. Shiffman*, Jean-Pierre Bronowicki, Stefan Zeuzem, Maribel Rodriguez-Torres, Stephen C. Pappas, David Nelson, Moises Diago
*VCU Medical Center, Richmond, VA, USA
![image002.gif](../images/120709/120709-3/image002.gif)
![image004.gif](../images/120709/120709-3/image004.gif)
![image006.gif](../images/120709/120709-3/image006.gif)
![image008.gif](../images/120709/120709-3/image008.gif)
![image010.gif](../images/120709/120709-3/image010.gif)
![image012.gif](../images/120709/120709-3/image012.gif)
![image014.gif](../images/120709/120709-3/image014.gif)
![image016.gif](../images/120709/120709-3/image016.gif)
![image018.gif](../images/120709/120709-3/image018.gif)
![image020.gif](../images/120709/120709-3/image020.gif)
![image022.gif](../images/120709/120709-3/image022.gif)
![image024.gif](../images/120709/120709-3/image024.gif)
![image026.gif](../images/120709/120709-3/image026.gif)
![image028.gif](../images/120709/120709-3/image028.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|